DURECT Corporation

DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies to treat serious and life-threatening conditions like acute organ injury and cancer. Their approach centers on epigenetic modulation, particularly targeting dysregulated DNA methylation. DURECT's lead drug candidate, larsucosterol, has shown promising results in clinical trials for the treatment of alcohol-associated hepatitis (AH), a life-threatening liver disease, and is in clinical development for this indication. They are also exploring the potential of larsucosterol to treat non-alcoholic steatohepatitis (NASH).

In addition to their epigenetic regulator program, DURECT also manufactures and sells ALZET Osmotic Pumps, which are miniature implantable pumps used for experimental research in laboratory animals. DURECT has a history of partnering with other companies, including Innocoll Pharmaceuticals, Orient Pharma, and Indivior PLC, to advance their drug development and commercialization efforts. The company is committed to developing innovative therapies that address unmet medical needs and improve patients' lives.

DURECT Corporation does not mention specific details about their job flexibility.

DURECT offers employees a comprehensive benefits package that includes a competitive salary, stock options, and a comprehensive benefits package. These benefits are designed to provide a rewarding work environment with opportunities for personal growth, high visibility within the scientific community, a collaborative and supportive team culture, and the chance to contribute to meaningful products that improve patients’ lives. DURECT also offers a convenient location and a competitive compensation package.

DURECT Corporation is a late-stage biopharmaceutical company dedicated to developing and commercializing epigenetic therapies that target dysregulated DNA methylation to revolutionize the treatment of serious and life-threatening conditions, particularly acute organ injury and cancer. Their mission is to harness the power of epigenetic modulation to offer patients with high unmet medical needs better therapeutic options and improve their quality of life.

DURECT Corporation fosters a highly collaborative and skilled team dedicated to unlocking the potential of epigenetic modulation. They promote a culture that prioritizes patient well-being, encourages trailblazing innovation, and upholds the highest ethical standards, fostering dedication, scientific excellence, and a supportive environment.

DURECT Corporation is committed to building a diverse, equitable, and inclusive workplace. The company believes that a diverse workforce fosters creativity, innovation, and better decision-making. DURECT strives to create an environment where everyone feels respected, valued, and empowered to contribute their unique perspectives and talents. The company actively works to attract, retain, and develop a diverse team of employees and creates opportunities for all employees to grow and succeed, regardless of their background or identity.